Graphene Flagship partner, the Istituto Italiano di Tecnologia, together with IRCCS Azienda Ospedaliera Metropolitana – Policlinico San Martino Hospital, has demonstrated that graphene oxide—used for the first time in the ophthalmic field—enhances the liquid artificial retina, increasing light sensitivity and recovery of visual function in advanced stages of retinitis pigmentosa. The study, published in Nature Communications, led to the restoration of electrical activity in the visual cortex, bringing this strategy closer to future clinical trials in humans.
Graphenea Semiconductor, a leading graphene foundry company and partner in the Graphene Flagship's 2D Pilot Line project and Melexis, a global supplier of micro-electronic semiconductor solutions, announces a strategic collaboration to accelerate the development and evaluation of Melexis’ integrated GFET-on-CMOS platform for advanced biosensing.
Recent research on various biomarkers for major depressive disorder (MDD) provide an opportunity to develop biosensors that can overcome the challenges faced by conventional diagnostic tools, MUNASET researchers say.
At the crossroads of cutting-edge materials science and advanced biomedical engineering, Jack Maughan is building tools that could reshape how we treat and interact with the brain. A postdoctoral researcher with a background in nanoscience and tissue engineering, Jack is exploring how graphene-based microneedles can enable next-generation neural interfaces devices that could one day treat neurological disorders, restore movement, and even enhance human-machine communication.
Welcome to the world of two-dimensional (2D) materials- Materials so thin, just a few atoms thick, which makes them both exceptionally lightweight and highly versatile. Some of these materials, such as graphene, are incredible strong, flexible, excellent conductors of electricity, and have a large surface area.
PRESS RELEASE - Strong collaboration among clinical, academic and industrial partners brings Europe a step closer to cost-effective point-of-care diagnostics for Alzheimer’s Disease.
